Growth Metrics

Zimmer Biomet Holdings (ZBH) Cost of Revenue (2016 - 2026)

Zimmer Biomet Holdings has reported Cost of Revenue over the past 18 years, most recently at $576.2 million for Q1 2026.

  • For Q1 2026, Cost of Revenue rose 4.8% year-over-year to $576.2 million; the TTM value through Mar 2026 reached $2.5 billion, up 13.07%, while the annual FY2025 figure was $2.5 billion, 13.81% up from the prior year.
  • Cost of Revenue for Q1 2026 was $576.2 million at Zimmer Biomet Holdings, down from $792.4 million in the prior quarter.
  • Over five years, Cost of Revenue peaked at $792.4 million in Q4 2025 and troughed at $488.2 million in Q3 2022.
  • A 5-year average of $550.8 million and a median of $538.6 million in 2024 define the central range for Cost of Revenue.
  • Biggest five-year swings in Cost of Revenue: decreased 3.02% in 2022 and later surged 35.06% in 2025.
  • Year by year, Cost of Revenue stood at $520.3 million in 2022, then increased by 3.56% to $538.8 million in 2023, then increased by 8.89% to $586.7 million in 2024, then surged by 35.06% to $792.4 million in 2025, then fell by 27.28% to $576.2 million in 2026.
  • Business Quant data shows Cost of Revenue for ZBH at $576.2 million in Q1 2026, $792.4 million in Q4 2025, and $559.3 million in Q3 2025.